Document is current
Any future updates will be listed below
-
Authors
Dave, Manas
Cheang, Maggie Chon U. https://orcid.org/0000-0001-5718-2501
Betts, Guy
Iwata, Tomoko https://orcid.org/0000-0002-9634-9738
Frost, Michelle
Braconi, Chiara https://orcid.org/0000-0003-4835-1259
Shamma, Menna
Kendall, Timothy J. https://orcid.org/0000-0002-4174-2786
-
Funding
Funding for this research was provided by:
Cancer Research UK (CTRQQR-2021\100006)
Cancer Research UK (CTRQQR-2021\100006)
- License Information
-
More Information
Article History
Received: 18 May 2026
Revised: 6 August 2026
Accepted: 24 August 2026
First Online: 1 September 2026
Ethics
Competing interests: CB received honoraria as a speaker from AstraZeneca, Incyte, Servier, and honoraria as a consultant from Incyte, Servier, Boehringer Ingelheim, AstraZeneca, Tahio, Jazz Pharmaceuticals, Molecular Partners, Delcath; received research funds from Avacta, Medannex, Servier, and her spouse is an employee of AstraZeneca. GB received honoraria as a consultant from MSD. MC is the co-inventor of PAM50/Prosigna, commercially licensed by Veracyte, with royalties paid, and serves as a scientific advisor for AstraZeneca. TJK has served as a consultant or advisory board member for Resolution Therapeutics, Clinnovate Health, HistoIndex, Fibrofind, Kynos Therapeutics, Perspectum, Concept Life Sciences, Servier Laboratories, Taiho Oncology, Roche, and Jazz Pharmaceuticals, and has received speakers’ fees from Servier Laboratories, Jazz Pharmaceuticals, AstraZeneca, HistoIndex, Taiho Oncology, and Incyte Corporation. The other authors do not declare any competing interests.
